The use of rFVIIa in non-haemophilia bleeding conditions in paediatrics

Prasad Mathew

doi:10.1160/TH04-03-0163

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 2004; 92(04): 738-746
DOI: 10.1160/TH04-03-0163

Theme Issue Article

Schattauer GmbH

The use of rFVIIa in non-haemophilia bleeding conditions in paediatrics

A systematic review

Prasad Mathew

¹University of New Mexico, Department of Pediatrics, Albuquerque, New Mexico, USA

› Author Affiliations

Abstract

Summary

From its original envisioned use in patients with hemophilia and inhibitors, recombinant factor VIIa has been increasingly used in a variety of non-hemophilia bleeding/hemorrhagic situations with great efficacy. Most of the reported work has been in adult patients. This paper sets out to review its use in the pediatric non-hemophilia patients and the varied conditions it has been tried and used. Most of the published literature has shown that this agent is efficacious, safe and can be used as an adjunctive measure in the achievement of hemostasis. However, most of the published work is mainly anecdotal, case reports or small series. Randomized trials in children are eagerly awaited.

Keywords

rFVIIa - children - non-hemophilia bleeding

Full Text

References

References
1 Hedner U. Recombinant activated factor VII as a universal hemostatic agent. Blood Coagul Fibrinolysis 1998; 09: S147-52.
2 Shapiro AD, Gilchrist GS, Hoots WK. et al. Prospective, randomized trial of two doses of rFVIIa (NovoSeven) in haemophilia patients with inhibitors undergoing surgery. Thromb Haemost 1998; 80: 773-8.
3 Mariani G, Testa MG, Di Paolantonio T. et al. Use of recombinant activated factor VII in the treatment of congenital factor VII deficiencies. Vox Sanguinis 1999; 77: 131-6.
4 Wong WY, Huang WC, Miller R. et al. Clinical efficacy and recovery levels of recombinant FVIIa (NovoSeven) in the treatment of intracranial haemorrhage in severe neonatal FVII deficiency. Haemophilia 2000; 06: 50-4.
5 Billio A, Pescosta N, Rosanelli C. et al. Successful short term oral surgery prophylaxis with rFVIIa in severe congenital factor VII deficiency. Blood Coagul Fibrinolysis 1997; 08: 249-50.
6 Brown JB, Emerick KM, Brown DL. et al. Recombinant factor VIIa improves coagulopathy caused by liver failure. JPGN 2003; 37: 268-72.
7 Chuansumrit A, Chantarojanasiri T, Isarangkura P. et al. Recombinant factor VIIa in children with acute bleeding resulting from liver failure and DIC. Blood Coagul Fibrinolysis 2000; 11 (Suppl. 01) S101-5.
8 Kalicinski P, Kaminski A, Drewniak T. et al. Quick correction of hemostasis in two patients with fulminant liver failure undergoing liver transplantation by recombinant activated factor VII. Transplant Proc 1999; 31: 378-9.
9 Chuansumrit A, Treepongkaruna S, Phuapradit P. Combined fresh frozen plasma with recombinant factor VIIa in restoring hemostasis for invasive procedures in children with liver diseases. Thromb Haemost 2001; 85: 748-9.
10 Young G, Nugent DJ. Prevention of bleeding complications in neonates with liver failure undergoing surgery using recombinant factor VIIa. Hematology 2001; 06: 341-6.
11 Tobias JD, Berkenbosch JW. Synthetic factor VIIa concentrate to treat coagulopathy and gastrointestinal bleeding in an infant with end-stage liver disease. Clin Pediatr 2002; 41: 613-6.
12 Al Douri M, Shafi T, Al Khudairi D. et al. Effect of the administration of recombinant activated factor VII (rFVIIa; NovoSeven) in the management of severe uncontrolled bleeding in patients undergoing heart valve replacement surgery. Blood Coagul Fibrinolysis 2000; 11 (Suppl. 01) S121-S7.
13 Tobias JD, Berkenbosch JW, Russo P. Recombinant factor VIIa to treat bleeding after cardiac surgery in an infant. Ped Crit Care Med 2003; 04: 49-51.
14 Kenet G. rFVIIa for profuse bleeding in surgical patients. Bloodline Rev 2001; 01: 12-13.
15 Leibovitch L, Kenet G, Mazor K. et al. Recombinant activated factor VII for lifethreatening pulmonary hemorrhage after pediatric cardiac surgery. Ped Crit Care Med 2003; 04: 444-6.
16 Greisen G, Andreasen RB. Recombinant factor VIIa in preterm neonates with prolonged prothrombin time. Blood Coagul Fibrinolysis 2003; 14: 117-20.
17 Veldman A, Fischer D, Voight B. et al. Lifethreatening hemorrhage in neonates: management with recombinant activated factor VII. Intensive Care Med 2002; 28: 1635-7.
18 Chuansumrit A, Nuntnarumit P, Okascharoen C. et al. The use of recombinant activated factor VII to control bleeding in a preterm infant undergoing exploratory laparotomy. Pediatrics 2002; 107: 169-71.
19 Olomu N, Kulkarni R, Manco-Johnson M. Treatment of severe pulmonary hemorrhage with activated recombinant factor VII in very low birth weight infants. J Perinatol 2002; 22: 672-4.
20 Tengborn L, Petruson B. A patient with Glanzmann thrombasthenia and epistaxis successfully treated with recombinant factor VIIa. Thromb Haemost 1996; 75: 981-2.
21 Poon MC, Demers C, Jobin F. et al. Recombinant factor VIIa is effective for bleeding and surgery in patients with Glanzmann Thrombasthenia. Blood 1999; 94: 3951-3.
22 Ancliff P, Leisner R, Khair K. et al. The use of recombinant factor VIIa in a patient with severe Glanzmann’s thrombasthenia to facilitate insertion of a Port-a-cath. Blood Coagul Fibrinolysis 1999; 10: 447-8.
23 Ameri A, Stolte S. Correlation of activated clotting time with rFVIIa infusion and clinical efficacy in a patient with Glanzmann Thrombasthenia and platelet alloantibodies. Thromb Haemost 2002; 87: 1084.
24 Chuansumrit A, Suwannuraks M, Sri-Udomporn N. et al. Recombinant activated factor VII combined with local measures in preventing bleeding from invasive dental procedures in patients with Glanzmann thrombasthenia. Blood Coagul Fibrinolysis 2003; 14: 187-90.
25 Devecioglu O, Unuvar A, Anak S. et al. Pyelolithomy in a patient with Glanzmann Thrombasthenia and antiglycoprotein IIb/IIIa antibodies: the shortest possible duration of treatment with recombinant activated factor VII and platelet transfusions. Turk J Pediatr 2003; 45: 64-6.
26 Caglar K, Cetinkaya A, Aytac S. et al. Use of recombinant factor VIIa for bleeding in children with Glanzmann thrombasthenia. Pediatr Hematol Oncol 2003; 20: 435-8.
27 Almeida AM, Khair K, Hann I. et al. The use of recombinant factor VIIA in children with inherited platelet function disorders. Br J Haematol 2003; 121: 477-81.
28 Peters M, Heijboer H. Treatment of a patient with Bernard-Soulier Syndrome and recurrent nosebleeds with recombinant factor VIIa. Thromb Haemost 1998; 80: 352.
29 Ciavarella N, Schiavoni M, Valenzano E. et al. Use of recombinant factor VIIa in the treatment of two patients with type III von Willebrand’s disease and an inhibitor against the von Willebrand factor. Haemostasis 1996; 26: 150-4.
30 Revesz T, Arets B, Bierings M. et al. Recombinant factor VIIa in severe uremic bleeding. Thromb Haemost 1998; 80: 353.
31 Kenet G, Walden R, Eldad A. et al. Treatment of traumatic bleeding with recombinant factor VIIa. Lancet 1999; 354: 1879.
32 Martinowitz U, Holcomb JB, Pusateri AE. et al. Intravenous rFVIIa administered for hemorrhage control in hypothermic coagulopathic swine wit highgrade V liver injuries. J Trauma 2001; 50: 721-9.
33 Martinowitz U, Kenet G, Segal E. et al. Recombinant activated factor VII for adjunctive hemorrhage control in trauma. J Trauma 2001; 51: 431-9.
34 Martinowitz U, Kenet G, Lubetsky A. et al. Possible role of recombinant factor VII (rFVIIa) in the control of hemorrhage associated with massive trauma. Can J Anesth 2002; 49 (10) S15-S20.
35 Morenski JD, Tobias JD, Jimenez DF. Recombinant activated factor VII for cerebralinduced coagulopathy in pediatric patients. J Neurosurg 2003; 98: 611-6.
36 Tobias JD, Groeper K, Berkenbosch JW. Preliminary experience with the use of recombinant factor VIIa to treat coagulation disturbances in pediatric patients. Southern Med J 2003; 96: 12-6.
37 Park P, Fewel ME, Garton HJ. et al. Recombinant activated factor VII for the rapid correction of coagulopathy in non-hemophilic neurosurgical patients. Neurosurgery 2003; 53: 34-9.
38 Mathew P, Winter SS, Frost JD. et al. Novel applications of recombinant factor VIIa for management of pediatric coagulopathic diseases. J Pediatr Hematol Oncol 2003; 25: 499-502.
39 Lusher J, Ingerslev J, Roberts H. et al. Clinical experience with recombinant factor VIIa. Blood Coagul Fibrinolysis 1998; 09: 119-28.
40 Roberts HR, Monroe DM, Hoffman M. Safety profile of recombinant factor VIIa. Semin Hematol 2004; 41: 101-8.
41 Hedner U, Erhardtsen E. Potential role for rFVIIa in transfusion medicine. Transfusion 2002; 42: 114-124.